Article: Appointments And Advancements.

Article: Ocera Therapeutics Inc. has added Mike Powell, managing director ...
San Diego Business Journal;  July 24, 2006 ;     700+ words ... ... number of boards. Anadys Pharmaceuticals Inc. has appointed James Freddo as chief medical officer. He will be responsible for leading ... Joint Steering Committee. Most recently, Freddo served as vice president of clinical site head and development site head for Pfizer ...

Article: ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels ...
PR Newswire;  April 23, 2009 ;     700+ words ... ... We're very pleased with the antiviral activity and safety of ANA598 in this study," commented James Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer. "We believe the data continue to position ANA598 ...

Article: ANA598 Receives Fast Track Designation From the FDA for the ...
PR Newswire;  December 1, 2008 ;     700+ words ... ... ANA598 acknowledges the need for new HCV therapies to improve treatment outcomes," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We anticipate continuing to work closely with ...

Article: Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C ...
PR Newswire;  October 28, 2008 ;     700+ words ... ... pharmacokinetics as a single dose in healthy volunteers in our recently concluded Phase I study," said James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We look forward to building upon these results ...

Article: Anadys Pharmaceuticals Commences Dosing in Phase II Study of ...
PR Newswire;  September 9, 2009 ;     700+ words ... ... properties indicative of likely synergy when used clinically in combination regimens," said James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We look forward to building upon these results ...

Article: Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C ...
Hepatitis Weekly;  November 10, 2008 ;     700+ words ... ... pharmacokinetics as a single dose in healthy volunteers in our recently concluded Phase I study," said James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We look forward to building upon these results ...

Article: ANA598 Demonstrates Potent Antiviral Activity in an Early ...
Hepatitis Weekly;  January 19, 2009 ;     700+ words ... ... antiviral activity and safety of ANA598 at this first dose tested in the Phase Ib study," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We believe this early data continues to position ...